argenx SE (NASDAQ:ARGX - Free Report) - Analysts at Wedbush raised their Q2 2025 EPS estimates for argenx in a research report issued on Thursday, February 27th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $4.22 per share for the quarter, up from their previous forecast of $4.15. Wedbush currently has a "Outperform" rating and a $655.00 target price on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenx's Q3 2025 earnings at $5.17 EPS, FY2025 earnings at $18.40 EPS and FY2028 earnings at $61.66 EPS.
argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million.
A number of other equities research analysts have also recently weighed in on the company. Robert W. Baird upped their price target on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a report on Tuesday. Evercore ISI upped their target price on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Wells Fargo & Company lifted their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Piper Sandler increased their price objective on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. Finally, William Blair restated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $662.83.
View Our Latest Stock Report on argenx
argenx Price Performance
argenx stock traded down $23.31 during mid-day trading on Monday, reaching $613.18. The company had a trading volume of 167,636 shares, compared to its average volume of 281,597. The stock's 50-day simple moving average is $642.47 and its 200-day simple moving average is $592.89. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The company has a market capitalization of $37.26 billion, a P/E ratio of -696.80 and a beta of 0.58.
Hedge Funds Weigh In On argenx
A number of large investors have recently bought and sold shares of ARGX. FMR LLC increased its holdings in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in argenx during the third quarter valued at about $88,339,000. Point72 Asset Management L.P. acquired a new stake in argenx during the fourth quarter worth about $91,013,000. Allspring Global Investments Holdings LLC raised its holdings in shares of argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after purchasing an additional 143,834 shares during the period. Finally, Marshall Wace LLP lifted its stake in shares of argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after purchasing an additional 124,271 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.
About argenx
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
